Trial Profile
Novel Use of the Proteasome Inhibitor Carfilzomib for Antibody Mediated Rejection After Lung Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Lung transplant rejection
- Focus Therapeutic Use
- 22 Dec 2015 New trial record